A multiple-ascending-dose study to evaluate the efficacy, safety, and pharmacokinetics (PK) of MEDI0382 in overweight and obese participants with Type 2 Diabetes Mellitus

Study identifier:D5670C00002

ClinicalTrials.gov identifier:NCT02548585

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Overweight and Obese Subjects with a History of Type 2 Diabetes Mellitus

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 1/2

Healthy volunteers

No

Study drug

MEDI0382, Placebo

Sex

All

Actual Enrollment

113

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 09 Dec 2015
Primary Completion Date: 24 Feb 2017
Study Completion Date: 24 Feb 2017

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2019 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria